Nasdaq
$11.28▼ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $223.3MShares out 19.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 9.29Pre-market26.09.29 21:018-KKey event#●●●#●●●
Keros Therapeutics, Inc.Bullish
Keros Therapeutics expects to receive a $20 million development milestone payment from its partner Takeda Pharmaceuticals following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The company plans to distribute 25% of the net cash proceeds from this milestone payment to its stockholders.…more
$11.28-0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28Pre-market26.09.28 21:018-KKey event
Keros Therapeutics, Inc.
Keros Therapeutics has initiated dosing for the first patient in its Phase 2 clinical trial of rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The trial aims to evaluate the safety and tolerability of the drug, with initial clinical data expected to be released in the first half of 2027.…more
$11.28-0.09%vs prev closeView filingShare - 9.17Pre-market26.09.17 13:15filedEFFECTOther
Keros Therapeutics, Inc.
Keros Therapeutics, Inc. received SEC effectiveness for its registration statement on September 16, 2026. This approval allows the company to proceed with the offering of securities as detailed in the filing.…more
$11.28-0.09%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 21:04Bullish#●●●#●●●
Keros Therapeutics to Receive $20M Milestone Payment from Takeda
Keros Therapeutics expects a $20 million milestone payment from Takeda following the first patient dosing in the Phase 3 ELRiSE MF clinical trial. The company plans to distribute 25% of the net proceeds from this payment to its stockholders.…more
$11.28-0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Pre-market26.09.29 21:00
●●●●●●●● ●●●●● ●●●●●●
Keros Therapeutics expects to receive a $20 million development milestone payment following the first patient dosing in Takeda's Phase 3 clinical trial. The company plans to distribute 25% of the net cash proceeds from this payment to its stockholders.…more
$11.28-0.09%vs prev close - 9.28Pre-market26.09.28 21:00
●●●●●●●● ●●●●● ●●●●●●
Keros Therapeutics has dosed the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). Initial data from the study is expected to be released in the first half of 2027.…more
$11.28-0.09%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report